Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RBP4 | P02753 | 6/20 | 0.53 |
| ▸ | DPP4 | P27487 | 2/20 | 0.51 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.48 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.44 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | HTR7 | P34969 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3098982 | 0.90 | FFAR1 (0.53) | RBP4DPP4FFAR1CHRNB4CHRNA3 | |
| SCHEMBL3113607 | 0.85 | DPP4 (0.52) | RBP4DPP4FFAR1CHRNB4CHRNA3 | |
| SCHEMBL3106079 | 0.84 | RBP4 (0.64) | RBP4DPP4FFAR1GAAMEN1 | |
| SCHEMBL3114289 | 0.81 | RBP4 (0.54) | RBP4DPP4FFAR1CHRNB4CHRNA3 | |
| SCHEMBL3110995 | 0.81 | RBP4 (0.49) | RBP4DPP4FFAR1CHRNB4CHRNA3 | |
| SCHEMBL18404641 | 0.80 | DPP4 (0.46) | RBP4DPP4FFAR1CHRNB4CHRNA3 | |
| SCHEMBL18404235 | 0.80 | DPP4 (0.48) | RBP4DPP4FFAR1CHRNB4CHRNA3 | |
| SCHEMBL13034496 | 0.80 | RBP4 (0.69) | RBP4DPP4HTR7 | |
| SCHEMBL13034528 | 0.79 | RBP4 (0.74) | RBP4HTR7 | |
| SCHEMBL18404334 | 0.79 | DPP4 (0.47) | RBP4DPP4FFAR1CHRNB4CHRNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2202223-B1 | HETEROCYCLIC COMPOUND AS BLOOD RBP4 LOWERING AGENT | TAKEDA PHARMACEUTICALS CO (JP) | 2017-01-25 | — | — | EP | disclosed |
| US-9487509-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-11-08 | — | — | US | disclosed |
| US-9487509-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-11-08 | — | — | US | disclosed |
| US-20140066420-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-03-06 | — | — | US | disclosed |
| US-20140066420-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-03-06 | — | — | US | disclosed |
| US-8586571-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-11-19 | — | — | US | disclosed |
| US-20100292206-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-11-18 | — | — | US | disclosed |
| US-20100292206-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140066420-A1 | HETEROCYCLIC COMPOUND | RBP4, RBP1, RAVER1 | RBP4 1/4885DPP4 104/4885FFAR1 2333/4885 |
| US-20100292206-A1 | HETEROCYCLIC COMPOUND | RBP4, RBP1, RAVER1 | RBP4 1/4885DPP4 104/4885FFAR1 2333/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.